Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH Sales of Investments

Cash received from selling or redeeming investments.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments dips below year-ago levels

Q2 FY2026 sales of investments of $99.03M fell 25.1% year over year, behind the +5.6% change in trailing-twelve-month sales of investments. Sequentially, it fell 9.1% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.

Context

  • Sales of investments amounted to 174.6% of revenue in FY2025, down 74.4 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -25.1% toward the trailing-twelve-month pace of +5.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$99.03M-9.1% QoQ
Last fiscal yearDec 2025
$494.13M-15.6% YoY
LTMJun 2026
$540.38M+5.6% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.1%——
1 year-15.6%——
3-year CAGR+2.1%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
494.13M USD
Year-over-year change
-15.6%
4-year CAGR
+8.7%

Sales of Investments vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 sales of investments of $540.38M is the 2nd largest of the 10 companies compared; the peer median is $185.26M.
  • Its year-over-year change of +5.6% is the 6th highest of 9, against a peer median of +42.0%.
  • Sales of investments amounts to 173.5% of revenue for AUPH, versus a peer median of 4228.9%.
AUPH Competitors Peer median
Sales of Investments for AUPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$555.15M +110.1%+46.4%7504.0%
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$540.38M +5.6%+2.1%173.5%
VERAVera Therapeutics, Inc.LTM Jun 2026$492.8M +18.2%+86.5%—
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$382.74M +65.8%+261.7%—
BHVNBiohaven Ltd.LTM Jun 2026$350M -46.3%——
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$185.26M +87.4%——
ATTOAttovia Therapeutics, Inc.FY2025$150.75M +1784.4%—11166.7%
EVMNEvommune, Inc.LTM Mar 2026$94.1M ——941.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$79.8M -19.5%-20.6%953.7%
TRAXFirst Tracks Biotherapeutics IncFY2025$0 -100.0%——
Peer median (excluding AUPH) $185.26M+42.0%+66.5%4228.9%

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
Deferred Income Tax0000(176.19M)
Stock-Based Compensation31.24M32.3M45.31M31.6M14.68M
Change in Working Capital(21.63M)(6.82M)(5.61M)5.45M(8.78M)
Accounts Receivables(15.42M)1.93M(10.61M)(12.46M)(4.91M)
Inventory(5.64M)(9.07M)(15.87M)477K(6.46M)
Accounts Payables4.08M(792K)1.24M860K(1.87M)
Other Working Capital(4.65M)1.12M19.63M16.57M4.46M
Other Non-Cash Items10.9M462K(6.79M)(17.85M)9.49M
Operating Cash Flow(157.69M)(79.53M)(33.46M)44.39M135.66M
Capital Expenditures(1.5M)(292K)(718K)(281K)(252K)
Acquisitions (Net)(1.2M)0000
Purchases of Investments(438.96M)(523.99M)(523.5M)(545.83M)(526.65M)
Sales of Investments354.43M464.32M529.38M585.42M494.13M
Other Investing Activities(16.63M)(663K)(11.86M)(43K)0
Investing Cash Flow(103.87M)(60.63M)(6.71M)39.26M(32.77M)
Debt Repayment00(10.03M)(11.99M)(13.14M)
Common Stock Issued196.74M00014.95M
Common Stock Repurchased000(40.24M)(98.16M)
Dividends Paid00000
Other Financing Activities24.37M2.43M4.9M3.14M(9.76M)
Financing Cash Flow221.11M2.43M(5.13M)(49.09M)(106.11M)
Effect of Forex Changes00000
Net Change in Cash(40.45M)(137.73M)(45.3M)34.56M(3.22M)
Free Cash Flow(159.19M)(79.82M)(34.18M)44.11M135.41M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.